Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: Rwanda briefly closed its border with Congo over the virus outbreak in the city of more than 2 million as the painstaking work of finding, tracking and vaccinating people who had contact with the man — and the contacts of those contacts — began. The man died on Wednesday after spending several days at home with his large family while showing symptoms. Congo’s presidency said the entire family was at “high risk” and in quarantine. The Ebola coordinator for North Kivu province, Dr. Aruna Abedi, confirmed the wife’s case to The Associated Press hours after that of the child. “We’re seeing the first active transmission chain in Goma and expect more to come,” the International Rescue Committee’s Ebola response director, Andre Heller, warned in a statement. This outbreak has killed more than 1,800 people, nearly a third of them children. It is now the second-deadliest Ebola outbreak in history, and last month the World Health Organization declared it a rare global emergency. Rwanda’s state minister for foreign affairs, Olivier Nduhungirehe, confirmed the border closure, a day after WHO officials praised African nations for keeping their borders open. Last week Saudi Arabia stopped issuing visas to people from Congo, citing the Ebola outbreak, shortly before the annual hajj pilgrimage there this month. Congo’s presidency condemned Rwanda’s decision, and Congolese at the busy frontier expressed frustration. “I can’t understand why they don’t just test us instead of closing these borders,” said Angel Murhula, who works in Rwanda. Several hours later Congo’s presidency said the border had reopened. A Rwanda health ministry statement called the events a “traffic slowdown” as surveillance for Ebola was reinforced. The ministry advised against unnecessary travel to the Goma area. WHO has recommended against travel restrictions amid the outbreak but says the risk of regional spread is “very high.” Any border closure is likely to push people to avoid official crossings equipped with hand-washing stations and where people are checked for signs of fever or other Ebola symptoms. In June, three people who crossed on an unguarded footpath into Uganda died there before their family members were taken back to Congo for treatment. The death Wednesday in Goma “in such a dense population center underscores the very real risk of further disease transmission, perhaps beyond the country’s borders,” United Nations agencies said in a joint statement marking a year of the outbreak. The man in his 40s was a miner returning from an area of northeastern Ituri province, Mongwalu, where no Ebola cases in this outbreak have been recorded, WHO said. He was exposed to the virus along the roughly 300-mile-long (490-kilometer) route from the city of Komanda to Goma as he took motor taxis over a number of days through the densely populated region at the heart of the outbreak. The man arrived in Goma on July 13 and started showing symptoms on July 22. He was isolated at an Ebola treatment center on Tuesday. He had spent five days being treated at home before going to a health facility, where Ebola was suspected. Symptoms can start to occur between two and 21 days from infection, health experts say. “He may not even have been aware of the exposure that he had,” WHO emergencies chief Dr. Michael Ryan said Wednesday. Symptoms such as fever can be confused with malaria, which is endemic in the region. Congo’s new Ebola response coordinator, Jean-Jacques Muyembe, has said there appears to be no link between the case and a previous one in Goma announced two and a half weeks ago. That case was a 46-year-old preacher who managed to pass through three health checkpoints on the way from Butembo, one of the communities hardest hit by this outbreak. The declaration of a global health emergency — the fifth in history —came days after that first Goma case. It has brought a surge of millions of dollars in new pledges by international donors, but some health workers say a new approach is needed to combat misunderstandings in a part of Congo that had never experienced Ebola before. Health workers responding to the outbreak have been attacked, even killed, in a region where rebel groups are active and the population is wary of outsiders. There is no licensed treatment for Ebola, which is spread by close contact with bodily fluids of those infected, and survival can depend on seeking treatment as quickly as possible. And yet many people in the region don’t believe that the virus is real, health workers have said. This outbreak is second only to the 2014-16 Ebola outbreak in West Africa that left more than 11,300 people dead. ___ Ssuuna reported from Kigali, Rwanda. Associated Press writer Al-Hadji Kudra Maliro contributed. ___ Follow Africa news at https://twitter.com/AP_Africa Claim: 1-year-old daughter, wife of Congo’s Goma victim have Ebola.
The wife and 1-year-old daughter of the man who died of Ebola in Goma this week have tested positive for the disease, health officials confirmed Thursday, the first transmission of the virus inside the densely populated crossroads city on the border with Rwanda, a scenario that health experts have long feared.

Paragraph: There was no mention of the potential costs of screening women for vitamin D levels (as encouraged in the release in a statement from the principal investigator) or the cost of supplementation. The release does a good job of comparing data and providing explanations for the measurements used. We’ll award a Satisfactory for that precision, but as noted below under “Evidence,” there was no explicit caution regarding the fact that measurements of interleukin-6 (IL-6) are only surrogates for the effects of weight loss and vitamin D on clinical outcomes related to inflammation (e.g. cancer diagnoses). IL-6 levels dropped in both the placebo and vitamin D arms, and it’s not clear whether the statistically significant additional decline in IL-6 observed in the vitamin D group is clinically important. Because some of the participants were vitamin D-deficient and the dose of vitamin D provided was modest (2000 IU/d), this was a tough call. But supplementation is often so misunderstood, overhyped and oversold that some statement cautioning readers to pay attention to the specifics of this study and not apply its recommendations to everyone seems prudent. For the most part, the release provides a cautious and accurate description of what appears to be a well-conducted clinical trial in a well-defined population. For example, it notes that weight loss and vitamin D lowered inflammation LINKED to cancer — not that these things reduced cancer risk itself (something this study couldn’t establish). But as noted above, we would have appreciated an explicit acknowledgment that IL-6 is a surrogate marker for the clinical outcomes that people care about. And more importantly, we’re concerned about the closing comment that women should talk to their doctors about measuring their vitamin D levels to determine the most appropriate dose. The problem is there is no evidence supporting screening or treating to a level — and certainly not from this study. The US Preventive Services Task Force has concluded that evidence is insufficient to recommend routine vitamin D screening and the IOM has said that while there are data supporting the benefits of vitamin D supplementation with bone health and fall prevention, there is no evidence supporting benefits for cancer. While testing may be warranted in those with signs or symptoms of clinical deficiency, the statement made here implies that everyone should be tested so that an appropriate dose of vitamin D can be selected. That goes beyond the available evidence. It’s hard to argue that overweight, vitamin deficiency, chronic inflammation and cancer are not real threats, so no mongering apparent here. Funding sources are well documented. The study didn’t discuss alternative preventive measures or genetic causes of increased cancer risks. But this is such a broad and expansive topic that we don’t think the release should have been expected to address those myriad issues. We’ll rate this Not Applicable. Primary care physicians and other health providers are well positioned to monitor blood levels of vitamin D, along with dietary and exercise regimens. The news release makes that clear, albeit indirectly. As noted above, we think the release goes too far in suggesting that people ask their doctors about having their vitamin D levels checked. But we’ve already docked points for that, so we’ll award a Satisfactory rating here. The release makes a case for this being the first clinical trial of its kind; although it’s always difficult to make that statement absolutely, the writer of the release attributes the statement to the study author. As a general rule, it’s probably best to say “believed to be the first.”  While the release meets our standard here, we also wish it had delved a bit into the background of previous vitamin D research and the conflicting and confusing messages that research has generated. Without that context, the typical reader might wrongly jump to the conclusion, based on the wording of the lede and other parts of the release, that this study of vitamin D supplementation — because it was a controlled clinical trial — has somehow settled the important questions about the role of vitamin D and inflammation in cancer risk. The debate remains alive and well. None detected. Claim: Weight loss plus vitamin D reduces inflammation linked to cancer, chronic disease
This news release describes a randomized, controlled clinical trial designed to learn whether adding vitamin D supplements to substantial weight loss regimens would have a synergistic effect in reducing inflammatory chemicals in the bodies of overweight, older women with levels of vitamin D considered too low. The study, published in Cancer Prevention Research, has potential relevance for cancer prevention because inflammatory cytokines have been implicated in the genesis and progression of some cancers, as well as heart disease and other disorders. The release offers substantial details about the design, metrics and outcomes of the clinical trial and does a pretty good job of defining the possible reasons for the effects of chronic inflammation and weight loss on cancer development. It goes to some lengths to narrowly define the results and avoid overstatement. That said, the release ends on a sour note by encouraging readers to talk to their doctors about vitamin D testing — a recommendation not consistent with U.S. Preventive Services Task Force guidelines and which is not supported by this research. Readers might also have been better informed if the release had offered more context regarding the many conflicting and sometimes confusing studies that have previously looked for links among vitamin D, inflammatory responses, diet, overweight, sun exposure and cancer. News releases that include the words “diet,” “overweight,” “vitamin,” and “cancer” are almost narrative nuclear events, often guaranteeing an explosion of coverage, souped up vitamin sales pitches, and lots of negative fallout whose half-life seems forever. Cancer remains the second biggest killer disease overall of Americans, and some experts believe that it will soon push heart disease and stroke out of first place. Thus cancer prevention is a deservedly hot topic, and it is no surprise that Americans are eager for information about ways to limit their risk. News releases that describe research on these topics have enormous power to inform and misinform.

Paragraph: Amid mounting global concern over the public health implications of so-called e-cigarettes, Touraine said they faced the same fate as traditional ones: a ban on smoking in public spaces and sales to minors and a blackout on media advertising. In a country where the pungent waft of Gaulloises and Gitanes once seemed an unassailable part of cafe culture, smokers have long been banished to outdoor terrace seats. The near-odorless electronic alternative - battery-driven devices that allow users inhale odorless nicotine-laced vapor rather than smoke - are gaining ground in no-go zones such as bars, cafes, trains, waiting rooms and offices. A government-commissioned report said this week that around 500,000 people in France had turned to e-cigarettes, which are designed to look like cigarettes although some come in different colors, and recommended a crackdown on public use. Health officials in many countries say the impact of electronic cigarettes on health needs further study. Another worry they cite is that the electronic alternative will increase the general temptation to smoke, including enticing those who have quit to start again, or that smokers may use them alongside rather than instead of regular cigarettes. “This is no ordinary product because it encourages mimicking and could promote taking up smoking,” said Touraine, who announced her plans at a news conference. In the United States, the number of smokers who have tried out e-cigarettes doubled to one in five in 2011 and the number of all adults trying it doubled too, to 6 percent, according to the U.S. Centers for Disease Control and Prevention. In France, a country of 66 million, the government says tobacco smoking kills some 66,000 people a year and another 5,000 are killed through passive exposure to smoke. The expert in charge of the French report advised against an outright ban on e-cigarettes, however, saying they still seemed safer than tar-laden tobacco. Electronic cigarettes, whose invention is widely credited to a Chinese pharmacist a decade ago, usually comprise disposable cartridges of liquid such as propylene glycol that is easily turned to vapor and can contain artificial flavors alongside concentrated liquid nicotine. Claim: France to ban electronic cigarettes in public.

France will ban electronic cigarette smoking in public places by imposing the same curbs enforced since 2007 to combat tobacco smoking, Health Minister Marisol Touraine said on Friday.